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depression. Our objective was to see if depression was present
in patients undergoing treatment for chronic pain with opioids
and if improving pain, improves depression. METHODS: A
standardized depression scale was administered to chronic stable
pain patients on opioids for chronic non-malignant pain. They
were scored and ranked. RESULTS: Out of 98 patients, only
15% had minimal to no depression by standardized testing.
There was good correlation with subsequent clinical evaluation.
Eighty-ﬁve percent (85%) had mild to severe depression. Those
with moderate to severe depression were referred for specialty
consultation. CONCLUSIONS: Depression is common in
chronic pain and the level of depression may not be predicted by
level of pain, analgesic, anti-depressant useage, or mental health
follow-up. Depression is easily missed and under-treated.
Depression does not always respond to the concomitant treat-
ment of pain. Patients with chronic pain should be regularly
screened for depression and appropriately referred for care.
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OBJECTIVE: Patients receiving strong opioids for chronic non-
malignant pain frequently experience adverse events, placing a
considerable burden on the patient and health care system. Evi-
dence suggests adverse event rates may vary between treatments.
METHODS: Patients treated with strong opioids for non-
malignant pain were identiﬁed using the General Practice
Research Database (GPRD). Three cohorts were identiﬁed: oral
oxycodone, oral modiﬁed release morphine, transdermal fen-
tanyl. Patients were matched for age, gender, morphine equiva-
lent dose and prior exposure to strong opioids. Adverse events
of interest were constipation and nausea and vomiting. Six
months of data were collected for each patient either side of their
ﬁrst prescription date (index date) for a strong opioid. Incidence
of treated adverse events was identiﬁed by prescription of laxa-
tives and anti-emetics during the 6-month post index, where no
prescription was present during the 6-month pre-index. Treat-
ment costs were estimated using the BNF. The chi square test
was used to test for differences in adverse event rates. RESULTS:
Incidence of constipation requiring treatment was estimated at
15% in the oxycodone cohort, 15% in the fentanyl cohort and
22% in the morphine cohort. Rates for oxycodone and fentanyl
were signiﬁcantly lower than morphine (p < 0.05). For nausea
and vomiting rates were 11%, 14%, and 14% respectively with
no signiﬁcant differences between cohorts. Mean treatment cost,
per case of constipation, was £19.34 for oxycodone, £41.71 for
fentanyl and £31.79 for morphine. For nausea and vomiting
costs were £13.10, £22.06 and £11.09. CONCLUSION: Patients
treated with morphine for non-malignant pain in this study were
more likely to be treated for constipation compared to oxy-
codone or fentanyl. Treatment for nausea and vomiting was
equally likely across treatment cohorts. Differences were
observed in the mean cost associated with adverse event treat-
ment. Further research would be valuable to conﬁrm the ﬁnd-
ings of this study.
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OBJECTIVES: Although use of long-acting opiod analgesics has
increased for chronic pain, little is known about treatment 
patterns. Purpose of this study was to compare ofﬁce-based 
utilisation data before and after initiating treatment with 
different long-acting opioids. METHODS: Retrospective analy-
sis of Disease Analyzer (MediPlus) data over 5 years for patients
with malignant diseases and orthopaedic diseases/chronic pain.
Patients have not been treated with opioids in the 18 months
before prescription. Observation period for resource utilisation
(outpatient consultations, referrals, dug costs) started 6 months
before and ended 6 months after ﬁrst index prescription for the
long-acting opioid of interest. RESULTS: Corresponding to the
course of the disease number of referrals, consultations, costs of
other drugs except of analgesics increased after initial prescrip-
tion of opioids. When opioids were administered, costs for other
analgesics decreased slightly compared to the pre-opioid period.
Drug costs differed signiﬁcantly. Highest opioid costs were deter-
mined for patients with malignant diseases which were treated
with fentanyl (mean 681€ in ﬁrst six months), followed by oxy-
codone (412€) and morphine (321€). Costs for opiod treatment
for patients with non-malignant chronic pain and orthopedic
conditions were 589€ (fentanyl), 370€ (oxycodone) and mor-
phine (243€) respectively. No signiﬁcant differences for costs for
other medication were found. Patients treated with oxycodone
showed signiﬁcant less consultations compared to fentanyl or
morphine. CONCLUSION: Type of opioid is an important
factor for costs of treatment of chronic pain in the ofﬁce-based
setting in Germany. The analysis indicates that other resource
utilization like consultation of physician could also be inﬂu-
enced. Due to the observational and retrospective nature of the
database study patient reported outcomes were not included.
Thus these outcomes and direct costs from hospitals associated
with long-acting opioids treatment would merit further analysis
in Germany.
PPN3
AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENT-
CONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN
ACADEMIC MEDICAL CENTER
Zhang M1,Viscusi E2, Costello A2,Vallow S3, Johnson N4
1Ortho-McNeil Pharmaceutical, Raritan, NJ, USA; 2Thomas Jefferson
University, Philadelphia, PA, USA; 3Janssen Medical Affairs, LLC,
Titusville, NJ, USA; 4Outcomes Research and Design, Inc, Houston,
TX, USA
OBJECTIVES: Intravenous patient-controlled analgesia (IV
PCA) is widely used for postoperative pain management. The
objectives of this pilot observational study were to deﬁne the
tasks and personnel required for IV PCA administration and to
identify problems arising with use of this modality. METHODS:
This study was conducted at a single site academic medical center
in Philadelphia, PA, USA. Process ﬂow diagrams were developed
based on interviews and observations conducted in the central
supply, biomedical engineering, pharmacy, and nursing depart-
ments. The diagrams mapped all steps in the process of IV PCA
administration within each department. Problems related to IV
PCA administration were also recorded. RESULTS: Forty-two
patients who underwent hip replacement surgery were selected
for observation. Central supply collected, cleaned, and delivered
IV PCA pumps to appropriate locations, and delivered malfunc-
tioning pumps to biomedical engineering. Biomedical engineer-
ing evaluated malfunctioning pumps and performed routine
maintenance on all pumps. Pharmacy prepared IV PCA syringes
and delivered them to the nursing units. Nursing staff processed
IV PCA orders, obtained pumps and set them up, redressed or
restarted IV lines, educated patients, discontinued PCA, and
